Product Description
Antithrombin III is a protein in the blood that blocks abnormal blood clots from forming. It helps the body keep a healthy balance between bleeding and clotting. Congenital antithrombin III deficiency is an inherited disease. It occurs when a person receives one abnormal copy of the antithrombin III gene from a parent with the disease. (Sourced from: https://medlineplus.gov/ency/article/000558.htm)
Mechanisms of Action: SP Inhibitor,Thrombin Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Indonesia | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Malta | Mexico | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Grifols
Company Location: NEW YORK NY 10036
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2020-001659-42 | P2 |
Completed |
COVID-19 |
2021-01-15 |
|
| jRCT2031230269 | P3 |
Recruiting |
Unknown |
1970-01-01 |